6:00pm - 6:15pm

• Welcome address
• François Degorce, Cisbio Bioassays - Bagnols-sur-Cèze, France

6:15pm - 7:15pm

• Keynote talk: Protein-complex assembly and GPCR signalling efficacy
• Michel Bouvier, Université de Montréal - Montréal, Canada

8:30am - 8:40am

• Session introduction
• Gérard Mathis, Cisbio Bioassays - Bagnols-sur-Cèze, France

8:40am - 9:10am

• Towards new terbium-based applications using second generation HTRF technology
• Eric Trinquet, Cisbio Bioassays - Bagnols-sur-Cèze, France

9:10am - 9:40am

• A Novel Double Epitope Tag for Rapid Quantification of Recombinant Protein with HTRF Technology
• Koji Enomoto, Shionogi - Osaka, Japan

9:40am - 10:10am

• HTRF in Process Analytical Technology (PAT)
• Esohe Idusogie, Oncomed Pharmaceuticals - Redwood City, USA

10:10am - 10:40am

• Coffee break

10:40am - 11:10am

• New HTRF tools to study GPCR associated complexes and function
• Jean-Philippe Pin, Institut de Génomique Fonctionnelle - Montpellier, France

11:10am - 11:40am

• Comparison of Functional Assays for Gq-coupled GPCRs by Measuring Inositol Monophosphate and Intracellular Calcium in 1536-well Plates
• Wei Zheng, National Institutes of Health - Rockville, USA

11:40am - 12:10pm

• Screening for Agonists and Antagonists of a GPCR through detection of IP-1 Accumulation in Cells.
• Jim LaRocque, Wyeth - Collegeville, USA

1:30pm - 1:40pm

• Session introduction
• Timothy Spicer, Scripps Institute - Jupiter, USA

1:40pm - 2:10pm

• Discovery of Novel Protein Kinase Inhibitors using TransTech Pharma's Translational Technology
• Stephen Davis, TransTech Pharma - High Point, USA

2:10pm - 2:40pm

• Kinase screening at the Laboratory for Drug Discovery, Harvard NeuroDiscovery Center
• Marcie Glicksman, Brigham and Women's Hospital - Cambridge, USA

2:40pm - 3:10pm

• Stoichiometry assessment of some kinase reactions using the ADP Transcreener
• Olivier Courtin, Sanofi-Aventis - Vitry-sur-Seine, France

3:10pm - 3:40pm

• Coffee break

3:40pm - 4:10pm

• The Current Status of HTRF Technology in Kinase Assays
• Yong Jia, Genomics Institute of the Novartis Research Foundation - San Diego, USA

4:10pm - 4:40pm

• Screening for inhibitors of serine/threonine Protein Kinases with HTRF, in order to identify lead compounds for anti-cancer drug development
• Martin Rowlands, Institute for Cancer Research - Sutton, UK

4:40pm - 5:10pm

• HTRF Assays in Kinase Screening at Merck Serono
• Ingo Kober, Merck-Serono - Darmstadt, Germany

5:10pm - 5:40pm

• HTRF Transcreener ADP assay: the new HTRF method measuring ADP generation
• Ingo Engels, Genomics Institute of the Novartis Research Foundation - San Diego, USA

8:30pm - 8:40pm

• Session introduction
• Rochdi Bouhelal, Novartis Pharma - Basel, Switzerland

8:40am - 9:10am

• Development and high throughput screening uisng IP1 and calcium mobilisation assays. Pharmacologial comparisons and case studies
• Rochdi Bouhelal, Novartis Pharma - Basel, Switzerland

9:10am - 9:40am

• Optimising cell-based HTRF assay formats for HTS and lead optimisation support
• Benjamin Bader, Bayer-Schering - Berlin, Germany

9:40am - 10:10am

• Assay Optimization and High Throughput Screening Using the cAMP Dynamic Range Kit
• Elaine Donohue, Novartis Pharma - Cambridge, USA

10:10am - 10:40am

• Coffee break

10:40am - 10:50am

• Session introduction
• Claudine Grépin, Sanofi-Aventis - Vitry-sur-Seine, France

10:50am - 11:20am

• Overview of HTRF screening formats: from biochemical to cell-based HTS
• Claudine Grépin, Sanofi-Aventis - Vitry-sur-Seine, France

11:20am - 11:50pm

• Analysing T-cell activation and differentiation using HTRF reagents
• Helmut Sparrer, Novartis Pharma - Basel, Switzerland

11:50am - 12:20pm

• Migration of ELISA-based Cytokine Assays to HTRF
• Jeremy Deguzman, Roche - Palo Alto, USA

Lunch break (12:20pm - 1:30pm)

1:30pm - 2:00pm

• Evaluation of the Cisbio HTRF SIRT1 assay as a tool for the discovery of small molecule modulators of Class III histone deacetylases.
• Thomas McDonagh, Elixir Pharmaceuticals - Cambridge, USA

2:00pm - 2:30pm

• Medium throughput in vitro confirmation of protein-protein interaction by HTRF. From interaction map to small molecule screening
• Jean-Christophe Rain, Hybrigenics - Paris, France

2:30pm - 3:00pm

• Optimization and screening of protein interaction assays using HTRF toolbox reagents
• Mike August, Boeringher Ingelheim Pharmaceuticals - Ridgefield, USA

3:00pm - 3:30pm

• Coffee break

3:30pm - 4:00pm

• Case study: Investigating PPARg coactivator recruitment by parallel HTRF® screens
• Franck Maddoux, Scripps Institute - Jupiter, USA

4:00pm - 4:30pm

• Evaluation and validation of the HTRF Insulin assay as a replacement for a commercially available ELISA
• Jeff Hixon, Elixir Pharmaceuticals - Cambridge, USA

4:30pm

• Conference closure